Abstract:Antimicrobial drug resistance poses a global health threat, requiring a deeper understanding of the evolutionary processes that lead to its emergence in pathogens. Complex evolutionary dynamics involve multiple mutations that can result in cooperative or competitive (clonal interference) effects. Candida albicans , a major fungal pathogen, displays high rates of copy number variation (CNV) and loss of heterozygosity (LOH). CNV and LOH events involve large numbers of genes and could synergize during evolutionary adaptation. Understanding the contributions of CNV and LOH to antifungal drug adaptation is challenging, especially in the context of whole-population genome sequencing. Here, we document the sequential evolution of fluconazole tolerance and then resistance in a C . albicans isolate involving an initial CNV on chromosome 4, followed by an LOH on chromosome R that involves KSR1 . Similar LOH events involving KSR1 , which encodes a reductase in the sphingolipid biosynthesis pathway, were also detected in independently evolved fluconazole resistant isolates. We dissect the specific KSR1 codons that affect fluconazole resistance and tolerance. The combination of the chromosome 4 CNV and KSR1 LOH results in a >500-fold decrease in azole susceptibility relative to the progenitor, illustrating a compelling example of rapid, yet step-wise, interplay between CNV and LOH in drug resistance evolution. The rise of drug-resistant microbes is a global health crisis. To combat this, we need to understand how these organisms evolve drug resistance. This study focuses on Candida albicans , a common fungal pathogen, and its ability to develop resistance to fluconazole, a widely used antifungal drug. We observe C . albicans rapidly evolve drug resistance through a two-step process involving large-scale genetic changes. First, it undergoes a copy number amplification, then it undergoes a loss of heterozygosity at the KSR1 gene, which is involved in sphingolipid biosynthesis. These changes work together to dramatically increase the fungus's ability to survive in the presence of the drug. This research highlights how quickly and efficiently yeast can adapt to overcome antifungal drug and emphasizes the importance of studying large-scale genetic changes, not just individual mutations, when investigating drug resistance. Our findings could help in developing new strategies to predict and prevent the emergence of resistant pathogens, ultimately improving patient care in the face of this growing threat.

Single-cell detection of copy number changes reveals dynamic mechanisms of adaptation to antifungals in Candida albicans

Use of Haploid Model of Candida Albicans to Uncover Mechanism of Action of a Novel Antifungal Agent.

Step-wise evolution of azole resistance through copy number variation followed by KSR1 loss of heterozygosity in Candida albicans

Candida albicans exhibits heterogeneous and adaptive cytoprotective responses to antifungal compounds

Step-wise evolution of azole resistance through copy number variation followed by loss of heterozygosity in

Chemogenomic Profiling of the Fungal Pathogen Candida Albicans

cDNA microarray analysis of differential gene expression and regulation in clinically drug-resistant isolates of Candida albicans from bone marrow transplanted patients

Recent gene selection and drug resistance underscore clinical adaptation across Candida species

Candida albicans gains azole resistance by altering sphingolipid composition

Aneuploidy Mediates Rapid Adaptation to a Subinhibitory Amount of Fluconazole in Candida albicans

Time Course of Global Gene Expression Alterations in Candida Albicans During Infection of Hela Cells

A Proteomic Landscape of Candida Albicans in the Stepwise Evolution to Fluconazole Resistance.

Optical Nanomotion Detection to Rapidly Discriminate between Fungicidal and Fungistatic Effects of Antifungals on Single-Cell Candida albicans

Long-term stability of acquired drug resistance and resistance associated mutations in the fungal pathogen Nakaseomyces glabratus (Candida glabrata)

DNA Microarray Analysis of Fluconazole Resistance in a Laboratory Candida Albicans Strain.

Genomic description of acquired fluconazole- and echinocandin-resistance in patients with serial Candida glabrata isolates

Chiral Fluorescent Antifungal Azole Probes Detect Resistance, Uptake Dynamics, and Subcellular Distribution in Candida Species

Proteomic Analysis Reveals a Metabolism Shift in a Laboratory Fluconazole-Resistant Candida Albicans Strain

Most azole resistance mutations in the Candida albicans drug target confer cross-resistance without intrinsic fitness cost

Adaptation to Fluconazole Via Aneuploidy Enables Cross-Adaptation to Amphotericin B and Flucytosine in Cryptococcus Neoformans

Tn-seq of the Candida glabrata reference strain CBS138 reveals epigenetic plasticity, structural variation, and intrinsic mechanisms of resistance to micafungin